Selective serotonin reuptake inhibitor use in primary care: A 5-year naturalistic study

Clinical Drug Investigation

Volumn 16, Issue 6, 1998, Pages 453-462

  Donoghue, John ^a,b,c  

^a CLATTERBRIDGE HOSPITAL   (United Kingdom)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; DEPRESSION; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0032423269     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816060-00005     Document Type: Article

References (27)

1. Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement. BMJ 1992; 305: 1198-202
2. Klerman GL, Weissman MM. The course, morbidity, and costs ofl depression. Arch Gen Psychiatry 1992; 49: 831-4
3. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the medical outcomes study. JAMA 1989; 262: 914-9
4. Hays RD, Wells KB, Sherbourne CD, et al. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry 1995; 52: 11-9
5. Freeling PR, Tylee A. Depression in general practice. In: Paykel ES, editor. Handbook of affective disorders. Edinburgh: Churchill Livingstone, 1992
6. Song F, Freemantle N, Sheldon T, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993; 306: 683-7
7. Anderson IM, Tomenson BM. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994; 8: 238-49
8. Hotopf M, Lewis G, Normand C. Are SSRIs a cost effective alternative to tricyclics? Br J Psychiatry 1996; 168: 404-9
9. Donoghue JM, Tylee A, Wildgust HJ. Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993-5. BMJ 1996; 313: 861-2
10. Finlay P. Selective serotonin reuptake inhibitors: pharmacological profiles and potential therapeutic distinctions. Ann Pharmacother 1994; 28: 1359-69
11. Leonard BE. The comparative pharmacology of new antidepressants. J Clin Psychiatry 1993; 15 (3 Suppl.): 54-8
12. Donoghue JM. A comparison of prescribing patterns of selective serotonin reuptake inhibitors in the treatment of depression in primary care in the United Kingdom. J Serotonin Res 1995: 1: 47-51
13. Donoghue JM. Prescribing patterns of selective serotonin reuptake inhibitors in primary care: a naturalistic follow up study. J Serotonin Res 1996; 4: 267-70
14. Gregor KJ, Overhage JM, Coons SJ, et al. Selective serotonin re-uptake inhibitor dose titration in the naturalistic setting. ClinTher 1994; 16: 306-15
15. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organisation. J Int Med Res 1995; 23: 395-412
16. Thompson D, Buesching D, Gregor KJ, et al. Patterns of antidepressant use and their relation to costs of care. Am J Manage Care 1996; 2: 1239-46
17. Montgomery SA, Bebbington P, Cowen P, et al. Guidelines for treating depressive illness with antidepressants: a statement from the British Association for Psychopharmacology. J Psychopharmacol 1993; 7: 19-23
18. Donoghue JM, Tylee A. The treatment of depression: prescribing patterns of antidepressants in primary care in the United Kingdom. Br J Psychiatry 1996; 168: 164-8
19. Dodd GK, Berti C. A critical appraisal of a naturalistic study to support cost effective prescribing patterns of selective serotonin reuptake inhibitors in primary care. J Serotonin Res 1997; 3: 169-72
20. Hylan TR, Crown WH, Meneades L, et al. Initial antidepressant selection and health care costs: a multivariate analysis. J Affect Disord 1998; 47: 71-9
21. Forder J, Kavanagh S, Fenyo A. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. J Affect Disord 1996; 38: 97-111
22. Hotopf M, Lewis G, Normand C. Putting trials on trial - the costs and consequences of small trials in depression: a systematic review of methodology. J Epidemiol Community Health 1997; 51: 354-8
23. Lane RM. Incentive bias? [letter]. J Clin Psychiatry 1996; 57: 265-7
24. Fahre LF, Abuzzahab FS, Amin M, et al. Sertraline safety and efficacy in major depression: a double blind fixed dose comparison with placebo. Biol Psychiatry 1995; 38: 592-602
25. Preskorn SH, Lane RM. Sertraline 50mg daily: the optimal dose in the treatment of depression. Int Clin Psychopharmacol 1995; 10: 129-41
26. Nemeroff CB. Dr Nemeroff Replies [letter]. J Clin Psychiatry 1996; 57: 267-9
27. Fisher S, Kent TA, Bryant SG. Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. J Clin Psychiatry 1995; 56: 288-96